Home/Filings/4/0001055726-22-000020
4//SEC Filing

Kim Jong Joseph 4

Accession 0001055726-22-000020

CIK 0001055726other

Filed

Mar 13, 8:00 PM ET

Accepted

Mar 14, 4:36 PM ET

Size

12.4 KB

Accession

0001055726-22-000020

Insider Transaction Report

Form 4
Period: 2022-03-11
Kim Jong Joseph
DirectorChief Executive Officer10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2022-03-11+139,3871,462,325 total
  • Tax Payment

    Common Stock

    2022-03-11$3.22/sh39,698$127,8281,422,627 total
  • Exercise/Conversion

    Restricted Stock Unit

    2022-03-11139,387139,386 total
    Common Stock (139,387 underlying)
Holdings
  • Common Stock

    (indirect: By Son: JK2)
    33,533
  • Common Stock

    (indirect: By Partnership)
    816,527
  • Common Stock

    (indirect: By Daughter: EK)
    33,563
  • Common Stock

    (indirect: By Son: JK1)
    33,775
  • Common Stock

    (indirect: By Spouse)
    5,975
Footnotes (2)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
  • [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.

Issuer

INOVIO PHARMACEUTICALS, INC.

CIK 0001055726

Entity typeother

Related Parties

1
  • filerCIK 0001464549

Filing Metadata

Form type
4
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 4:36 PM ET
Size
12.4 KB